UNLABELLED: In a study of 2005 institutionalized older people, use of oral bisphosphonates was associated with a 27% reduction in risk of death compared to non-users after adjusting for potential confounders. INTRODUCTION: This study investigated whether reductions in mortality reported in a trial of intravenous zoledronate after hip fracture could be seen in older people taking oral bisphosphonates. METHODS: Two thousand and five institutionalized older people (mean age 85.7 years) were assessed at baseline and followed up for hip fracture and death for at least 5 years. Cox proportional hazards regression was used to estimate effects of bisphosphonates on risk of death. RESULTS: At baseline, 78 subjects were taking oral bisphosphonates. Over 5 years of follow-up, 1,596 participants (80%) died. Use of bisphosphonates was associated with a 27% reduction in risk of death compared to non-users after adjusting for age, gender, type of institution, immobility, number of medications, weight, cognitive function, co-morbidities, and hip fracture incidence during the follow-up period (hazard ratio 0.73; 95% CI, 0.56 to 0.94; P = 0.02). CONCLUSION: Oral bisphosphonates are associated with a reduction in the risk of death in the elderly. The mechanism of effect requires further investigation.
UNLABELLED: In a study of 2005 institutionalized older people, use of oral bisphosphonates was associated with a 27% reduction in risk of death compared to non-users after adjusting for potential confounders. INTRODUCTION: This study investigated whether reductions in mortality reported in a trial of intravenous zoledronate after hip fracture could be seen in older people taking oral bisphosphonates. METHODS: Two thousand and five institutionalized older people (mean age 85.7 years) were assessed at baseline and followed up for hip fracture and death for at least 5 years. Cox proportional hazards regression was used to estimate effects of bisphosphonates on risk of death. RESULTS: At baseline, 78 subjects were taking oral bisphosphonates. Over 5 years of follow-up, 1,596 participants (80%) died. Use of bisphosphonates was associated with a 27% reduction in risk of death compared to non-users after adjusting for age, gender, type of institution, immobility, number of medications, weight, cognitive function, co-morbidities, and hip fracture incidence during the follow-up period (hazard ratio 0.73; 95% CI, 0.56 to 0.94; P = 0.02). CONCLUSION: Oral bisphosphonates are associated with a reduction in the risk of death in the elderly. The mechanism of effect requires further investigation.
Authors: J Zochling; Y Y Sitoh; T C Lau; I D Cameron; R G Cumming; S R Lord; J Schwarz; A Trube; L M March; P N Sambrook Journal: Osteoporos Int Date: 2002-11 Impact factor: 4.507
Authors: Philip N Sambrook; Charles J S Chen; Lyn March; Ian D Cameron; Robert G Cumming; Stephen R Lord; Judy M Simpson; Markus J Seibel Journal: J Bone Miner Res Date: 2006-04-05 Impact factor: 6.741
Authors: Dennis M Black; Pierre D Delmas; Richard Eastell; Ian R Reid; Steven Boonen; Jane A Cauley; Felicia Cosman; Péter Lakatos; Ping Chung Leung; Zulema Man; Carlos Mautalen; Peter Mesenbrink; Huilin Hu; John Caminis; Karen Tong; Theresa Rosario-Jansen; Joel Krasnow; Trisha F Hue; Deborah Sellmeyer; Erik Fink Eriksen; Steven R Cummings Journal: N Engl J Med Date: 2007-05-03 Impact factor: 91.245
Authors: P N Sambrook; J S Chen; L M March; I D Cameron; R G Cumming; S R Lord; J Zochling; Y Y Sitoh; T C Lau; J Schwarz; M J Seibel Journal: J Clin Endocrinol Metab Date: 2004-04 Impact factor: 5.958
Authors: Ian D Cameron; Jian Sheng Chen; Lyn M March; Judy M Simpson; Robert G Cumming; Markus J Seibel; Philip N Sambrook Journal: J Bone Miner Res Date: 2010-04 Impact factor: 6.741
Authors: Cathleen S Colón-Emeric; Peter Mesenbrink; Kenneth W Lyles; Carl F Pieper; Steven Boonen; Pierre Delmas; Erik F Eriksen; Jay Magaziner Journal: J Bone Miner Res Date: 2010-01 Impact factor: 6.741
Authors: Dana Bliuc; Nguyen D Nguyen; Vivienne E Milch; Tuan V Nguyen; John A Eisman; Jacqueline R Center Journal: JAMA Date: 2009-02-04 Impact factor: 56.272
Authors: Robert A Adler; Ghada El-Hajj Fuleihan; Douglas C Bauer; Pauline M Camacho; Bart L Clarke; Gregory A Clines; Juliet E Compston; Matthew T Drake; Beatrice J Edwards; Murray J Favus; Susan L Greenspan; Ross McKinney; Robert J Pignolo; Deborah E Sellmeyer Journal: J Bone Miner Res Date: 2016-01 Impact factor: 6.741
Authors: Frederick Wolfe; Marcy B Bolster; Christopher M O'Connor; Kaleb Michaud; Kenneth W Lyles; Cathleen S Colón-Emeric Journal: J Bone Miner Res Date: 2013-05 Impact factor: 6.741